Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.36 |
| ▸ | PYGB | P11216 | 2/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512365 | 0.99 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL4064968 | 0.96 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL18660236 | 0.91 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17748428 | 0.89 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28843545 | 0.88 | SLC28A1 (0.37) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL2546576 | 0.88 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL29508997 | 0.87 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6389231 | 0.86 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL4849439 | 0.86 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Acetic Acid SCHEMBL27645915 | 0.84 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168243-A1 | CORONAVIRUS TREATMENT COMPOSITIONS AND METHODS | UNIV NEW YORK STATE RES FOUND (US) | 2022-06-02 | — | — | US | disclosed |
| EP-1180113-A4 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS INC (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1180113-A1 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066609-A1 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168243-A1 | CORONAVIRUS TREATMENT COMPOSITIONS AND METHODS | ACE, SARS1, ACE2 | SLC28A1 2452/4885SLC28A2 3341/4885SLC29A1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.